Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2014

01-04-2014 | Original Article

Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population

Authors: Xian-Bo Zuo, Yu-Jun Sheng, Su-Juan Hu, Jin-Ping Gao, Yang Li, Hua-Yang Tang, Xian-Fa Tang, Hui Cheng, Xian-Yong Yin, Lei-Lei Wen, Liang-Dan Sun, Sen Yang, Yong Cui, Xue-Jun Zhang

Published in: Rheumatology International | Issue 4/2014

Login to get access

Abstract

Our previous genome-wide association studies on SLE have identified several susceptibility genes involved in NF-κB signaling pathway, including TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3. The aim of this study is to investigate the association model (additive, dominant, recessive) of these genes and search for possible gene–gene interactions between them. In this study, we explored the association model of these six genes and search for possible gene–gene interactions based on identified single-nucleotide polymorphisms (SNPs) among them by using logistic regression analysis in the combined sample of 4,199 cases and 8,255 controls. The most significant association evidence was observed under recessive model for all of these SNPs. Besides, significant interactions between these SNPs were observed in this study: the TNFSF4 and TNIP1 SNPs (P adjusted = 1.68E−10), the TNFSF4 and SLC15A4 SNPs (P adjusted = 3.55E−08), the TNFSF4 and UBE2L3 SNPs (P adjusted = 8.74E−13), the TNIP1 and BLK SNPs (P adjusted = 9.45E−10), the TNIP1 and UBE2L3 SNPs (P adjusted = 8.25E−11), the TNFAIP3 and UBE2L3 SNPs (P adjusted = 3.06E−14) and the BLK and SLC15A4 SNPs (P adjusted = 4.51E−12). These results may contribute to our understanding of SLE genetic interactions and account for the additional risk of certain patients to develop SLE.
Literature
1.
Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318PubMedCrossRef
2.
Luan H, Li P, Cao C et al (2012) A single-nucleotide polymorphism of the STAT4 gene is associated with systemic lupus erythematosus (SLE) in female Chinese population. Rheumatol Int 32:1251–1255PubMedCrossRef
3.
4.
Fernando MM, Stevens CR, Sabeti PC et al (2007) Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet 3:e192PubMedCentralPubMedCrossRef
5.
Yao Z, Hartung K, Deicher HG et al (1993) DNA typing for HLA-DPB1-alleles in German patients with systemic lupus erythematosus using the polymerase chain reaction and DIG-ddUTP-labelled oligonucleotide probes. Members of SLE Study Group. Eur J Immunogenet 20:259–266PubMedCrossRef
6.
Hartung K, Baur MP, Coldewey R et al (1992) Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 90:1346–1351PubMedCentralPubMedCrossRef
7.
Karassa FB, Trikalinos TA, Ioannidis JP (2002) Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 46:1563–1571PubMedCrossRef
8.
Salmon JE, Millard S, Schachter LA et al (1996) Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97:1348–1354PubMedCentralPubMedCrossRef
9.
Lee YH, Rho YH, Choi SJ et al (2007) The PTPN22 C1858T functional polymorphism and autoimmune diseases—a meta-analysis. Rheumatology (Oxford) 46:49–56CrossRef
10.
Kyogoku C, Langefeld CD, Ortmann WA et al (2004) Genetic association of the R620 W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75:504–507PubMedCentralPubMedCrossRef
11.
Graham RR, Kyogoku C, Sigurdsson S et al (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 104:6758–6763PubMedCentralPubMedCrossRef
12.
Graham RR, Kozyrev SV, Baechler EC et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555PubMedCrossRef
13.
Sigurdsson S, Nordmark G, Goring HH et al (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76:528–537PubMedCentralPubMedCrossRef
14.
15.
Cunninghame Graham DS, Graham RR, Manku H et al (2008) Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 40:83–89PubMedCentralPubMedCrossRef
16.
Cui Y, Sheng Y, Zhang X (2013) Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 41:25–33PubMedCrossRef
17.
Kim K, Brown EE, Choi CB et al (2012) Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Ann Rheum Dis 71:1809–1814PubMedCentralPubMedCrossRef
18.
Castillejo-Lopez C, Delgado-Vega AM, Wojcik J et al (2012) Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis 71:136–142PubMedCentralPubMedCrossRef
19.
Zhou XJ, Lu XL, Nath SK et al (2012) Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus. Arthritis Rheum 64:222–231PubMedCrossRef
20.
Han JW, Zheng HF, Cui Y et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41:1234–1237PubMedCrossRef
21.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
22.
Ritchie MD, Hahn LW, Roodi N et al (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69:138–147PubMedCentralPubMedCrossRef
23.
Moore JH, Gilbert JC, Tsai CT et al (2006) A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241:252–261PubMedCrossRef
24.
Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene–gene and gene-environment interactions. Bioinformatics 19:376–382PubMedCrossRef
25.
Velez DR, White BC, Motsinger AA et al (2007) A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol 31:306–315PubMedCrossRef
26.
Cherkassky V, Ma Y (2009) Another look at statistical learning theory and regularization. Neural Netw 22:958–969PubMedCrossRef
27.
Lou XY, Chen GB, Yan L et al (2007) A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 80:1125–1137PubMedCentralPubMedCrossRef
28.
29.
Mahdi H, Fisher BA, Kallberg H et al (2009) Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 41:1319–1324PubMedCrossRef
30.
Morgan AW, Thomson W, Martin SG et al (2009) Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum 60:2565–2576PubMedCrossRef
31.
Perdigones N, Vigo AG, Lamas JR et al (2010) Evidence of epistasis between TNFRSF14 and TNFRSF6B polymorphisms in patients with rheumatoid arthritis. Arthritis Rheum 62:705–710PubMedCrossRef
32.
Kallberg H, Padyukov L, Plenge RM et al (2007) Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80:867–875PubMedCentralPubMedCrossRef
33.
34.
Boone DL, Turer EE, Lee EG et al (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5:1052–1060PubMedCrossRef
35.
Wertz IE, O’Rourke KM, Zhou H et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694–699PubMedCrossRef
36.
Beyaert R, Heyninck K, Van Huffel S (2000) A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 60:1143–1151PubMedCrossRef
37.
Saijo K, Schmedt C, Su IH et al (2003) Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol 4:274–279PubMedCrossRef
38.
Lee J, Tattoli I, Wojtal KA et al (2009) pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J Biol Chem 284:23818–23829PubMedCentralPubMedCrossRef
39.
Orian A, Whiteside S, Israel A et al (1995) Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. J Biol Chem 270:21707–21714PubMedCrossRef
40.
Orozco G, Eyre S, Hinks A et al (2011) Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 70:463–468PubMedCentralPubMedCrossRef
41.
Fransen K, Visschedijk MC, van Sommeren S et al (2010) Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn’s disease. Hum Mol Genet 19:3482–3488PubMedCrossRef
Metadata
Title
Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population
Authors
Xian-Bo Zuo
Yu-Jun Sheng
Su-Juan Hu
Jin-Ping Gao
Yang Li
Hua-Yang Tang
Xian-Fa Tang
Hui Cheng
Xian-Yong Yin
Lei-Lei Wen
Liang-Dan Sun
Sen Yang
Yong Cui
Xue-Jun Zhang
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2864-3

Other articles of this Issue 4/2014

Rheumatology International 4/2014 Go to the issue

Short Communication

Common variants of a urate-associated gene LRP2 are not associated with gout susceptibility

Short Communication

Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results

Short Communication

Adverse effects of methotrexate in three psoriatic arthritis patients

Letter to the Editors

Two brucellosis cases with vasculitic skin lesions

Original Article

Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus

Letter to the Editors

Peripheral arterial disease in patients with Behçet’s disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits